Altimmune to Participate at the H.C. Wainwright Global Life Sciences Conference

GAITHERSBURG, Md., March 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. ALT, a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at H.C. Wainwright Global Life Sciences Conference, being held April 8-10 in Monte Carlo, Monaco.

Presentation Details - H.C. Wainwright Global Life Sciences Conference

Date: Tuesday, April 10, 2018
Time: 9:25am Eastern Time/3:25pm Central European Time
Location: LeMeridien Beach Plaza Hotel, Monte Carlo, Salon Atlantique-Meridional
Webcast: http://wsw.com/webcast/hcw2/alt/

About Altimmune

Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

Contacts:

Bill Enright

President and CEO

Phone: 240-654-1450

enright@altimmune.com

Ashley Robinson

LifeSci Advisors, LLC

617-535-7742

arr@lifesciadvisors.com

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!